Novel melatonin-based therapies: potential advances in the treatment of major depression

Ian B Hickie, Naomi L Rogers

Major depression is one of the leading causes of premature death and disability. Although available drugs are effective, they also have substantial limitations. Recent advances in our understanding of the fundamental links between chronobiology and major mood disorders, as well as the development of new drugs that target the circadian system, have led to a renewed focus on this area. In this review, we summarise the associations between disrupted chronobiology and major depression and outline new antidepressant treatment strategies that target the circadian system. In particular, we highlight agomelatine, a melatonin-receptor agonist and selective serotonergic receptor subtype (ie, 5-HT2c) antagonist that has chronobiologic, antidepressant, and anxiolytic effects. In the short-term, agomelatine has similar antidepressant efficacy to venlafaxine, fluoxetine, and sertraline and, in the longer term, fewer patients on agomelatine relapse (23.9%) than do those receiving placebo (50.0%). Patients with depression treated with agomelatine report improved sleep quality and reduced waking after sleep onset. As agomelatine does not raise serotonin levels, it has less potential for the common gastrointestinal, sexual, or metabolic side-effects that characterise many other antidepressant compounds.

Introduction

Major depression is a leading cause of premature death and ongoing disability.12 Although the therapeutic benefits of drugs for less severe forms of depression is debatable,3,4 the overall value that results from the wider benefits of drugs for less severe forms of depression is destigmatisation of depression and anxiety.5,6

More regular and extensive use of appropriate health services, decreased risk of cardiovascular disease, and, through reduced secondary alcohol or other substance misuse, suicide rates, increased participation in the workforce, patients with depression is clear. Benefits include reduced circadian cycles and sleep architecture, and the adverse effects of many antidepressant drugs on immune, cardiovascular and metabolic systems 11

Circadian and sleep–wake systems

The circadian system is central to the maintenance of the daily sleep–wake cycle and sense of wellbeing. This system coordinates key physiological components, including the sleep–wake, thermoregulatory, endocrine, immune, cardiovascular and metabolic systems11

Search strategy and selection criteria

This article is not a systematic review. We searched PubMed for articles on “melatonin”, “melatonin analogues”, “melatonin analogs”, “agomelatine”, “ramelteon”, “tasimelteon”, “PD-6735”, “depression”, “antidepressants”, “circadian disruption”, “circadian rhythms”, “chronotherapeutics”, “chronobiotics”, and “sleep”. Only papers or abstracts published in English were reviewed. Searches were done for the period 1948 to February, 2011. The “agomelatine” search was supplemented with information from the US National Institutes of Health ClinicalTrials.gov website, the International Standard Randomised Controlled Trial Number Register website, and the European Medicines Agency website. This search was also supplemented with information from contact with the manufacturer of agomelatine (Servier Laboratories) and suggested additional references from reviewers of this article.
early waking, and advancing of the secretory rhythms of melatonin, cortisol, and norepinephrine; figure 1B), whereas others have phase delays (ie, late sleep-onset with delayed morning-waking; figure 1C).

There are also reductions in the amplitude of diurnal variations of other key features such as core-body temperature or plasma concentrations of cortisol. Under conditions of internal desynchronisation (figure 1D), the timing of several circadian rhythms (eg, core body-temperature, plasma concentrations of melatonin and cortisol, sleep–wake timing) are out of phase both with each other and the external environment.11

In our opinion, this breakdown in the internal links between key sleep, mood, cognitive, and other physiological cycles results in polyphasic sleep patterns, excessive sleepiness or fatigue while awake, depressed mood, and impaired neurocognition.

Most patients with depression have prolonged sleep latencies and a high frequency of arousals and awakenings during the night. Consequently, hypersomnia, daytime fatigue, or napping might be prominent.20 Additionally, polysomnographically defined changes in sleep architecture in patients with depression include decreased time spent in slow-wave sleep, reduced periods of rapid eye-movement (REM) sleep, reduced latency to the first REM episode, and increased amounts of stage 1 and stage 2 sleep.21 Although non-REM sleep (stage 1, stage 2, and slow-wave sleep) is mainly regulated by the homeostatic sleep system, REM sleep is modulated by the circadian system.22 The goal of antidepressant treatment is not only to restore sleep–wake patterns but also to resynchronise circadian-dependent biology and its link with the external environment.

**Disruption of circadian function as a cause of neuropsychiatric disorders**

There has been increased emphasis on the possibility that disturbed circadian function is a major risk factor to a range of neuropsychiatric disorders. From this perspective, disturbance of circadian rhythms (independent of specific diagnosis) results in a phenotype characterised by depressed mood, daytime fatigue, poor concentration, mood, and impaired neurocognition.

Behavioural or pharmacological interventions that focus on the restoration of normal circadian function result not only in substantial improvements in mood but also in substantial improvements in cognition and daytime fatigue.23

**Circadian limitations of current treatments of major depression**

For more than 50 years, drug treatments for major depression have targeted monoamine systems. Although many of the older tricyclic drugs had beneficial effects on sleep onset or sleep duration (mostly via histaminergic mechanisms), they also suppressed REM sleep. In fact, REM suppression was previously thought to be an...
essential feature of antidepressant compounds. The most commonly prescribed selective serotonin-reuptake inhibitors often disrupt slow-wave sleep and REM cycles (at least in the short term) and do not necessarily restore normal circadian function.

These adverse effects of new antidepressants often result in the co-prescription of other sedative drugs. In severe cases of depression, adjunctive therapy with second-generation antipsychotic drugs that have prominent sedative or mood-stabilising properties (eg, olanzapine or quetiapine) is now commonplace. Hypnotic drugs that simply reduce sleep onset or night-time awakenings do not relieve depression. Similarly, drugs that are purely sedative have only limited effects on restoring normal chronobiology, and long-term treatment poses high risks of tolerance and addiction.

Restoration of normal chronobiology is increasingly thought to be a marker of effectiveness for antidepressant treatments. Failure to restore normal rhythms is highly predictive of ongoing symptoms or early relapse.

A circadian focus for antidepressant treatments

A circadian focus for treatments of depression places emphasis not only on the restoration of normal daily variations in the sleep–wake cycle, but also on the restoration and synchronisation of other key neuro-hormonal (eg, variations in plasma concentrations of melatonin and cortisol), physiological (eg, body temperature), and neurocognitive signs (eg, alertness). A prerequisite is re-entrainment of the circadian system to the cues in the external environment. Several strategies are available to achieve this goal, including appropriately timed exposure to bright or blue light, treatment with melatonin, and restructuring of sleep–wake timing. One study reported positive effects of combining pharmacological interventions with adjunctive circadian-based therapies (ie, sleep deprivation, exposure to bright light, and sleep-phase advance) to reduce depressive symptoms in patients with bipolar disorder. In patients who were randomly assigned to receive the adjunctive circadian-based interventions (n=32), a significantly greater antidepressant effect was evident 48 h after the start of treatment (effect size 0·56, p=0·03), which was sustained for up to 7 weeks (0·51, p=0·02), compared with patients who received drugs alone (n=17).

Recently, several melatonin analogues have been developed and, as expected, they showed chronobiotic effects. Some of the drugs that have traditionally been used in the management of mood disorders also affect key regulatory aspects of the circadian system. The mood stabiliser lithium produces phase delay, and might increase the circadian period. More recently, the chronobiotic effects of lithium have been reported to be probably attributable to its action on glycogen synthase kinase 3β, which is a central regulator of the endogenous circadian clock.

**Behavioural manipulation of the circadian system**

Several behavioural treatments focus on manipulation of the circadian and related sleep–wake systems. The main target has typically been the sleep phase, with less emphasis on increasing daytime activity (particularly in the morning period) or reduction in daytime napping. Total or partial sleep deprivation during the second half of the night has short-term antidepressant effects. The antidepressant effect of sleep deprivation is reversed after subsequent sleep episodes, and periods of repeated sleep deprivation result in a build-up of a sleep debt. This effect has adverse consequences on normal daytime wakefulness, neurocognitive functioning, and safety (eg, while driving a motor vehicle or operating machinery).

Exposure to chronic sleep restriction (7–14 days), with allowable time in bed limited to less than 6 h per night, results in cumulative deficits in neurocognitive performance. The negative effects of sleep restriction on neurocognitive outcomes are reversed after recovery sleep. Other studies have indicated similar effects with fewer days of sleep restriction, in addition to changes in

<table>
<thead>
<tr>
<th>SNP</th>
<th>Effect</th>
<th>Other notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>GSK3β</td>
<td>Bipolar disorder</td>
<td>Target of lithium; central regulator of circadian clock</td>
</tr>
<tr>
<td>CLOCK</td>
<td>Bipolar disorder</td>
<td>T3J11T SNP: CC genotype is associated with greater insomnia in patients undergoing antidepressant treatment, and greater insomnia and decreased need for sleep in patients with bipolar disorder</td>
</tr>
<tr>
<td>ARNTL (also known as BMAL1 or MOP3)</td>
<td>Bipolar disorder</td>
<td>Data from SNP and haplotype analysis studies</td>
</tr>
<tr>
<td>PER3</td>
<td>Bipolar disorder, seasonal affective disorder</td>
<td>Bipolar disorder data from haplotype analysis studies</td>
</tr>
<tr>
<td>TIMELESS (also known as TIM1)</td>
<td>Bipolar disorder</td>
<td>Data from SNP analysis studies</td>
</tr>
<tr>
<td>PER2, Npas2, ARNTL</td>
<td>Seasonal affective disorder</td>
<td>Combinations of these genes result in additive effects and thus further increased risk of seasonal affective disorder</td>
</tr>
</tbody>
</table>

GSK3β=glycogen synthase kinase 3β; CLOCK=clock homologue. SNP=single-nucleotide polymorphism. ARNTL=aryl hydrocarbon receptor nuclear translocator-like. PER=period homologue. TIMELESS=timeless homologue. Npas2=neuronal PAS domain-containing protein gene 2. McClung, Partonen and colleagues, Wulff and colleagues, and Mansour and colleagues provide further details of the links between circadian genes and affective disorders.  

Table 1: Genetic overlap between the circadian system and affective disorders
a range of physiological functions, including melatonin secretion\(^6\) and metabolic variables.\(^6\)

Although bright-light therapy can reverse depressive symptoms, this technique has mainly been used in patients with seasonal affective disorder (also known as winter depression).\(^7\) The effectiveness of bright-light exposure is assumed to result from the acute daytime suppression of melatonin, resulting in long-term phase-shifts and restoration of an appropriate relation with the external environment. Even though most studies of bright-light therapy have been done in patients with seasonal affective disorder, several short-term studies, of small sample size, have indicated efficacy with bright-light therapy for non-seasonal depression.\(^3\)–\(^4\) In a Cochrane meta-analysis,\(^5\) bright-light therapy alone, or as an adjunct to either antidepressant drugs or to sleep deprivation, had some modest effects. Recently, the circadian system was reported to be most sensitive to light in the blue wavelength range (460 nm),\(^6\) thereby allowing lower intensities of light to be used to achieve equivalent phase shifts.

Melatonin
Melatonin has high affinity for two receptors (MT\(_1\), and MT\(_2\)), which are located throughout the brain, including in the suprachiasmatic nucleus of the hypothalamus, substantia nigra, hippocampus, cerebellum, ventral tegmental area, and nucleus accumbens.\(^1\)–\(^3\) These brain areas are involved in regulating various homeostatic systems, including sleep–wake activity and thermoregulation. The exact roles of these two G-protein-coupled receptors is not clear, and the ratios of expression of the two receptors might be important for some of the actions of melatonin.\(^7\) Changes in the brain content and the ratio of MT\(_1\) to MT\(_2\) receptors have been reported in neurodegenerative disorders (eg, Alzheimer’s disease),\(^8\) with similar changes reported after chronic antidepressant use.\(^1\)–\(^3\) Although a third melatonin binding site (MT\(_3\)) has been identified,\(^9\) melatonin binds to this site with much lower affinity and its role is less clear.

Melatonin is produced and secreted in the pineal gland. In healthy individuals without disrupted chronobiology or depression, melatonin’s secretion is high at night with only negligible circulating concentrations during daylight hours.\(^10\) Melatonin has an important role in the circadian timing system by binding to receptors in the suprachiasmatic nucleus and to other cells and systems throughout the body.\(^1\)–\(^3\) Melatonin’s binding to the suprachiasmatic nucleus has two effects: inhibition of neuronal firing in the suprachiasmatic nucleus and entrainments or phase shifts in circadian rhythms.\(^1\) Additionally, nocturnal elevation in melatonin’s plasma concentrations is associated with increased sleep propensity, reduced body temperature, and decreased alertness.\(^1\)–\(^3\)

Exogenous melatonin treatment
Melatonin is now widely available in the USA where it is deemed to be a dietary supplement. Different formulations of melatonin are sold internationally, with both immediate-release and sustained-release options available. Appropriately timed administration of melatonin has chronobiotic properties and can assist with phase shifting the circadian system (either alone or, more typically, in combination with light exposure).\(^1\) In addition to its chronobiotic effects, melatonin also increases sleep propensity, reduces sleep latency, decreases alertness and neurocognitive functioning, and lowers core body temperature. Although these outcomes are desirable at night, they might be thought of as adverse effects if melatonin is given during the day.\(^1\)

Is melatonin an antidepressant?
Exogenous melatonin has some antidepressant-like actions in animal models.\(^1\) Daily treatment with melatonin reverses the adverse effects of chronic stress in mice.\(^3\) By contrast, treatment with melatonin alone in human beings does not seem to be an effective antidepressant strategy.\(^1\) Although melatonin might improve sleep–wake timing and increase sleep duration in patients with major depressive disorder, there seem to be few more specific antidepressant effects.\(^1\) Addition of chronobiotic drugs such as melatonin to currently used antidepressant therapies can, however, improve overall outcomes.\(^1\)–\(^3\)

Although some antidepressants improve several sleep variables, including sleep efficiency and increasing the amount of REM sleep, others (eg, tricyclic antidepressants and selective serotonin-reuptake inhibitors) have negative effects on sleep architecture, reducing the duration of REM sleep and increasing REM latency.\(^1\) Because REM sleep is under circadian control, this latter finding might indicate changes in the circadian system rather than in the sleep system. As disruptions to other variables affected by the circadian system, including melatonin, core temperature, and cortisol, are also common in patients with depression, antidepressant treatments should target these broader domains. The compounds that bind melatonergic receptors might be expected to have such effects.

Melatonin analogues
By contrast with most formulations of melatonin available commercially, the development of specific melatonin analogues means that we now have access to compounds that are being systematically evaluated pharmacologically and behaviourally. Although all melatonin analogues have been investigated for their sleep-promoting effects, they differ in their chemical structure and binding affinities for MT\(_1\), and MT\(_2\). Additionally, one compound, agomelatine, also binds to the 5-HT\(_1A\) and 5-HT\(_2C\) receptors and has been studied more extensively as a primary antidepressant drug. Table 2 lists a summary of actions of melatonin analogues. Rajaratnam and colleagues\(^1\) provide further detail about the animal studies done with these compounds.
Circadin
Melatonin in the Circadin formulation works in the same way as does endogenous melatonin at the MT, and MT, receptors, and reduces the time to fall asleep and improves the quality of sleep and morning alertness in people aged over 55 years with insomnia.61,67

Ramelteon
Ramelteon has high affinity for MT, and MT, receptors and low affinity for MT, binding sites.44 In studies of transient insomnia and chronic insomnia, done in both general adult and older adult populations, ramelteon had a modest effect on sleep latency and total sleep time.64,69–73 In these studies, patients were allocated a set time in bed for sleep; consequently, the increase in total sleep time induced by ramelteon was attributable to the reduction in the time taken to fall asleep. Ramelteon has been approved by the US Food and Drug Administration (FDA) for the treatment of insomnia, particularly in individuals in whom insomnia is associated with delayed sleep onset.

Tasimelteon
This compound has high affinity for MT, and MT, receptors and produces phase shifts, in animal models, that are of similar magnitude to those induced by melatonin.74 In human beings, there is evidence of improvements in the latency to sleep and improved sleep maintenance, when sleep was attempted at an earlier phase than normal (ie, during the early afternoon).65 Additionally, there is notable phase shifting after treatment with tasimelteon, with dose-dependent phase advances in the timing of the dim-light melatonin onset after a 5-h phase advance of the light–dark cycle.65

PD-6735
This compound is a selective agonist at MT, and MT, receptors with substantial chronobiotic and soporific properties. In patients with chronic primary insomnia, reductions in sleep latency were reported after a range of doses.66 After a 9-h phase advance of the light–dark cycle, PD-6735 increased the rate of re-entrainment in a range of circadian rhythms, including those of core body temperature, and plasma concentrations of cortisol, potassium, sodium, and chloride.66

Table 2: Effects of melatonin and melatonin analogues

<table>
<thead>
<tr>
<th>Hormone</th>
<th>Trade names</th>
<th>Approval</th>
<th>Binding</th>
<th>Sleep effects</th>
<th>Chronobiotic effects</th>
<th>Antidepressant effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Melatonin</td>
<td>Neurim Pharmaceuticals</td>
<td>EMA 2007</td>
<td>MT, MT, MT</td>
<td>Promotes sleep initiation, especially during biological day (ie, when endogenous concentrations are low)</td>
<td>Phase advance and phase delay; entrains circadian system</td>
<td>Synergistic effects when given adjunctively with antidepressant and when given alone in animals</td>
</tr>
<tr>
<td>Melatonin (Neurim Pharmaceuticals)</td>
<td>Circadin</td>
<td>EMA 2007</td>
<td>MT, MT, MT</td>
<td>Mimics the endogenous melatonin profile by releasing melatonin gradually over 8–10 h</td>
<td>Phase advance</td>
<td>No data available</td>
</tr>
<tr>
<td>Analogues</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Agomelatine (Servier)</td>
<td>Valdoxan, Melitor, Thymovanax</td>
<td>EMA 2009</td>
<td>MT, MT, 5-HT (antagonist), 5-HT (antagonist)</td>
<td>Significant benefits in patients with depression</td>
<td>Phase advance, entrains circadian system</td>
<td>Yes: major depressive disorder in adults</td>
</tr>
<tr>
<td>Ramelteon (Takeda Pharmaceutical Company)</td>
<td>Rozerem</td>
<td>FDA 2005</td>
<td>MT, MT</td>
<td>Decreased sleep latency, increased total sleep time in patients with insomnia, reduction in slow-wave sleep</td>
<td>Phase advance</td>
<td>No data available</td>
</tr>
<tr>
<td>Tasimelteon (VEC-126, Vanda Pharmaceuticals)</td>
<td>FDA phase 3 clinical trial completed 2010, orphan drug designation 2010</td>
<td>MT, MT</td>
<td>Promotes sleep initiation and sleep maintenance (tested during 5-h phase advance) and concurrent shift in endogenous circadian rhythms</td>
<td>Phase advance and phase delay</td>
<td>No data available</td>
<td></td>
</tr>
<tr>
<td>TIK 301 (PD-6735, LY-156, 735, Tikvah Pharmaceuticals)</td>
<td>FDA phase 2 clinical trial since 2002, orphan drug designation 2004</td>
<td>MT, MT</td>
<td>Decreased sleep latency in patients with insomnia</td>
<td>Promotes phase advance</td>
<td>No data available</td>
<td></td>
</tr>
</tbody>
</table>

MT=melatonin receptor. EMA=European Medicines Agency. 5-HT=serotonin receptor. FDA=US Food and Drug Administration. Rajaratnam and colleagues37 provide further details of effects of melatonin and melatonin analogues. *All receptors are agonistic unless otherwise specified.

Figure 2: Structure of melatonin (N-acetyl-5-methoxytryptamine) and agomelatine (N-[2-(7-methoxy-1-naphthyl)ethyl] acetamide)
Agomelatine

Agomelatine is unique in that it is a selective agonist at MT₁ and MT₂ receptors and an antagonist at 5-HT₂B and 5-HT₂C receptors. Figure 2 shows the chemical structures of agomelatine and melatonin. Agomelatine has a rapid absorption rate: the time at which maximum blood concentration was achieved was between 45 min and 90 min after a single oral dose of 25–50 mg. After

<table>
<thead>
<tr>
<th>Table 3: Summary of placebo-controlled and active comparator trials of agomelatine in human beings</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CL2-014</strong></td>
</tr>
<tr>
<td>Agomelatine 1 mg per day</td>
</tr>
<tr>
<td>Agomelatine 5 mg per day</td>
</tr>
<tr>
<td>Agomelatine 25 mg per day</td>
</tr>
<tr>
<td>Paroxetine 20 mg per day</td>
</tr>
<tr>
<td>Placebo</td>
</tr>
</tbody>
</table>

| **CL3-025** |
| Agomelatine 25 mg per day | 129 | 27.6 (2.9) | 14.5 (8.2) | 1.17 (p=0.193) | 5.0 (0.5) | 3.3 (1.4) | 0.19 (NS) |
| Fluoxetine 20 mg per day | 133 | 27.3 (2.8) | 13.3 (7.6) | 2.55 (p=0.055) | 5.0 (0.6) | 3.1 (1.4) | 0.38 (p≤0.05) |
| Placebo | 147 | 28.0 (3.6) | 15.9 (8.6) | -- | 5.0 (0.6) | 3.5 (1.5) | -- |

| **CL3-029** |
| Agomelatine 25 mg per day | 141 | 25.7 (2.8) | 13.0 (8.0) | 0.63 (p=0.504) | 4.6 (0.7) | 2.9 (1.3) | 0.17 (NS) |
| Placebo | 137 | 26.1 (2.9) | 12.2 (8.1) | 1.58 (p=0.055) | 4.6 (0.7) | 2.7 (1.3) | 0.37 (p≤0.05) |

| **CL3-044** |
| Agomelatine 25 mg per day | 148 | 26.4 (3.0) | 12.0 (8.2) | 0.90 (p=0.291) | 4.7 (0.7) | 2.9 (1.4) | 0.17 (NS) |
| Agomelatine 50 mg per day | 147 | 26.5 (3.4) | 13.4 (8.2) | 0.41 (p=0.629) | 4.8 (0.7) | 3.0 (1.4) | 0.02 (NS) |
| Fluoxetine 20 mg per day | 146 | 26.5 (3.4) | 12.5 (7.4) | 0.53 (p=0.536) | 4.7 (0.7) | 2.9 (1.3) | 0.11 (NS) |
| Placebo | 158 | 26.9 (3.4) | 13.4 (8.4) | -- | 4.7 (0.7) | 3.0 (1.4) | -- |

| **CL3-046 (in an elderly population >60 years)** |
| Agomelatine 25 mg per day | 129 ≥24 (MADRS) | 10.6 (9.4) (MADRS) | 0.19 (p=0.89) | NR | NR | NR |
| Placebo | 109 ≥24 (MADRS) | 9.6 (8.7) (MADRS) | -- | NR | NR | NR |

| **CAGO178A2302 (NCT00411242)** |
| Agomelatine 25 mg per day | 158 | 26.8 (SE 0.3) | 14.1 (SE 0.6) | 2.2 (p=0.010)† | 4.8 (0.7) | 3.2 (1.3) | 0.44 (p=0.017)† |
| Placebo | 163 | 26.4 (SE 0.2) | 17.1 (SE 0.6) | -- | 4.8 (0.7) | 3.6 (1.3) | -- |

| **CAGO178A2301 (NCT00411099)** |
| Agomelatine 25 mg per day | 158 | 26.8 (SE 0.3) | 15.0 (SE 0.6) | 2.2 (p=0.010)† | Only presented graphically | NR | NR |
| Placebo | 167 | 26.7 (SE 0.3) | 16.5 (SE 0.6) | -- | 4.8 (0.7) | 3.6 (1.3) | -- |

| **CAGO178A2303 (NCT00463242)** |
| Agomelatine 25–50 mg per day | 162 | 27.2 (SE 0.3) | 17.1 (SE 0.6) | 0.5 (p=0.539)† | NR | NR | NR |
| Placebo | 167 | 27.1 (SE 0.3) | 16.6 (SE 0.7) | -- | NR | NR | NR |

Values are mean (SD) unless otherwise stated. HAM-D=Hamilton Rating Scale for Depression. CGI-S=Clinical Global Impression—severity of illness scale. CGI-I=Clinical Global Impression—improvement scale. NS=not significant. MADRS=Montgomery-Åsberg Depression Rating Scale. NR=not reported. SE=standard error. *Sample size used for analysis. †Difference in final score for agomelatine-treated patients versus final score for comparator patients. ‡These values are estimated differences. §Studies are thought to have failed if the active drug did not separate from placebo. Additional agomelatine trials for the treatment of major depressive disorder that have recently been completed but are yet to be published include NCT00463242, NCT00467402 (prevention of relapse), NCT00411099, ISRCTN96725312 (CL3-062), ISRCTN68222771 (CL3-048; elderly population), ISRCTN68371813 (CL2-005), ISRCTN55250367 (CL3-063), and ISRCTN44737909 (CL3-056).
oral ingestion, agomelatine undergoes high hepatic first-pass metabolism, which contributes to the wide degree of interindividual variability in bioavailability. Further factors affecting bioavailability include sex, use of oral contraceptives, and smoking. Circulating agomelatine is mainly bound to plasma proteins (>90%) and is almost completely metabolised (with up to 80% of the dose excreted in the urine as metabolites). The mean terminal half-life is 140 min. There is an increase in dopamine and norepinephrine concentrations in the prefrontal cortex that results from antagonism of the 5-HT₂C receptors.

Although agomelatine has expected chronobiotic effects, it also has clinically significant antidepressant and anxiolytic properties. These psychotropic effects have been proposed to be caused by the synergy between the melatonin-based (MT₁, MT₂ receptor-dependent) and monoamine-based (5-HT₂C receptor-dependent) effects. This compound might also achieve its antidepressant effect via some other non-circadian mechanism, such as increased production of brain-derived neurotrophic factor.

Treatment with agomelatine in young, healthy men 5 h before bedtime produced a phase advance in the circadian

### Table 4: Summary of active comparator and prevention of relapse trials of agomelatine in human beings

<table>
<thead>
<tr>
<th>Active comparator trials</th>
<th>HAM-D score (baseline)</th>
<th>HAM-D score (at end)</th>
<th>Difference †</th>
<th>CGI-S/I score (baseline)</th>
<th>CGI-S/I score (end)</th>
<th>Difference †</th>
</tr>
</thead>
<tbody>
<tr>
<td>CL3-046 (ISRCTN45576288)</td>
<td>150</td>
<td>26·1 (2·8)</td>
<td>10·3 (7·0)</td>
<td>1·68 (p=0·031)</td>
<td>4·7 (0·7)</td>
<td>2·5 (1·1)</td>
</tr>
<tr>
<td>Agomelatine 25–50 mg per day</td>
<td>157</td>
<td>26·5 (3·0)</td>
<td>12·1 (8·3)</td>
<td>-</td>
<td>4·7 (0·7)</td>
<td>2·8 (1·3)</td>
</tr>
<tr>
<td>Sertraline 50–100 mg per day</td>
<td>165</td>
<td>25·9 (3·2)</td>
<td>9·9 (6·6)</td>
<td>1·1 (p=0·154)</td>
<td>3·2 (0·8)</td>
<td>1·6 (0·7)</td>
</tr>
<tr>
<td>CL3-035</td>
<td>167</td>
<td>26·0 (3·3)</td>
<td>11·0 (7·4)</td>
<td>-</td>
<td>3·6 (0·9)</td>
<td>1·6 (0·8)</td>
</tr>
<tr>
<td>Agomelatine 50 mg per day</td>
<td>137</td>
<td>27·9 (4·1)</td>
<td>10·1 (7·8)</td>
<td>0·3 (p=0·751)</td>
<td>4·4 (NR)</td>
<td>NR</td>
</tr>
<tr>
<td>Venlafaxine 75–150 mg per day</td>
<td>139</td>
<td>27·9 (4·6)</td>
<td>9·8 (7·9)</td>
<td>-</td>
<td>4·5 (NR)</td>
<td>NR</td>
</tr>
<tr>
<td>CL3-045 (ISRCTN19313268)</td>
<td>247</td>
<td>28·5 (2·7)</td>
<td>11·1 (7·3)</td>
<td>1·49 (p=0·024)†</td>
<td>5·0 (0·6)</td>
<td>2·6 (1·3)</td>
</tr>
<tr>
<td>Agomelatine 25–50 mg per day</td>
<td>257</td>
<td>28·7 (2·5)</td>
<td>12·7 (8·5)</td>
<td>-</td>
<td>5·0 (0·6)</td>
<td>2·8 (1·4)</td>
</tr>
<tr>
<td>Fluoxetine 20–40 mg per day</td>
<td>71</td>
<td>26·1 (2·3)</td>
<td>NR</td>
<td>1·46 (p=0·002)</td>
<td>4·7 (0·6)</td>
<td>NR</td>
</tr>
<tr>
<td>CL3-056</td>
<td>67</td>
<td>26·0 (2·9)</td>
<td>NR</td>
<td>-</td>
<td>4·7 (0·7)</td>
<td>NR</td>
</tr>
<tr>
<td>Agomelatine 25–50 mg per day</td>
<td>104</td>
<td>22·6 (2·4)</td>
<td>6·1 (3·5)</td>
<td>0·9 (p=0·064)</td>
<td>4·1 (0·8)</td>
<td>1·6 (0·8)</td>
</tr>
<tr>
<td>Escitalopram 10–20 mg per day</td>
<td>124</td>
<td>22·9 (2·2)</td>
<td>5·2 (2·2)</td>
<td>-</td>
<td>4·2 (0·8)</td>
<td>1·6 (0·7)</td>
</tr>
<tr>
<td>Paroxetine 20 mg per day</td>
<td>88</td>
<td>22·6 (2·4)</td>
<td>6·1 (3·5)</td>
<td>0·9 (p=0·064)</td>
<td>4·1 (0·8)</td>
<td>1·6 (0·8)</td>
</tr>
<tr>
<td>Placebo</td>
<td>124</td>
<td>22·9 (2·2)</td>
<td>5·2 (2·2)</td>
<td>-</td>
<td>4·2 (0·8)</td>
<td>1·6 (0·7)</td>
</tr>
<tr>
<td>Prevention of relapse or recurrence trials</td>
<td>24 weeks</td>
<td>165</td>
<td>6·1 (2·6)</td>
<td>7·5 (7·0)</td>
<td>3·13 (p&lt;0·001)</td>
<td>1·8 (0·8)</td>
</tr>
<tr>
<td>Agomelatine 25–50 mg per day</td>
<td>174</td>
<td>6·0 (2·7)</td>
<td>10·6 (8·4)</td>
<td>-</td>
<td>1·8 (0·7)</td>
<td>2·6 (1·5)</td>
</tr>
<tr>
<td>Placebo</td>
<td>165</td>
<td>6·1 (2·6)</td>
<td>7·8 (7·4)</td>
<td>3·69 (p&lt;0·001)</td>
<td>1·8 (0·8)</td>
<td>2·1 (1·3)</td>
</tr>
<tr>
<td>Placebo</td>
<td>174</td>
<td>6·0 (2·7)</td>
<td>11·5 (8·6)</td>
<td>-</td>
<td>1·8 (0·7)</td>
<td>2·7 (1·5)</td>
</tr>
<tr>
<td>CL3-035</td>
<td>185</td>
<td>6·0 (2·7)</td>
<td>9·3 (7·4)</td>
<td>0·32 (NS)</td>
<td>1·8 (0·8)</td>
<td>2·3 (1·5)</td>
</tr>
<tr>
<td>Agomelatine 25 mg per day</td>
<td>179</td>
<td>6·2 (2·7)</td>
<td>9·6 (7·5)</td>
<td>-</td>
<td>1·8 (0·8)</td>
<td>2·3 (1·5)</td>
</tr>
<tr>
<td>Placebo</td>
<td>185</td>
<td>6·0 (2·7)</td>
<td>9·3 (7·4)</td>
<td>0·32 (NS)</td>
<td>1·8 (0·8)</td>
<td>2·3 (1·5)</td>
</tr>
</tbody>
</table>

Values are mean (SD). HAM-D=Hamilton Rating Scale for Depression. CGI-S=Clinical Global Impression—severity of illness scale. CGI-I=Clinical Global Impression—improvement scale. MADRS=Montgomery-Åsberg Depression Rating Scale. NR=not reported. NS=not significant. OR=odds ratio. *Sample size used for analysis. †Difference in final score for agomelatine-treated patients versus final score for comparator patients.

These values are estimated differences. Studies are thought to have failed if the active drug did not separate from placebo. Additional agomelatine trials for the treatment of major depressive disorder that have recently been completed but are yet to be published include NCT00463242, NCT00467402 (prevention of relapse), NCT00411099, ISRCTN96725312 (CL3-062), ISRCTN68222771 (CL3-048; elderly population), ISRCTN38378163 (CL2-005), ISRCTN55250367 (CL3-063), and ISRCTN44737909 (CL3-056).
New Drug Class

timing of the temperature and melatonin rhythms and advanced the timing of the daily decrease in heart rate.\(^8\) The termination of the sleep period and REM sleep-propensity were also phase-advanced, with no other effects reported on sleep variables.\(^81\) Consistent phase-shifting effects were also reported in a later study of healthy elderly men, with advances in the timing of the temperature and cortisol rhythms induced by agomelatine, again with no effect on any sleep variables.\(^82\) Antidepressant-like effects of agomelatine have been reported in animal studies.\(^83\) In human beings, an extensive set of randomised controlled trials have been completed.\(^84\)–\(^86\) Typical therapeutic doses in these trials were 25–50 mg of agomelatine. Comparator antidepressants included fluoxetine, paroxetine, sertraline, and venlafaxine (table 3 and table 4). Of the three published placebo-controlled trials used to support drug registration,\(^87\)–\(^89\) the absolute difference in response rates (ie, 50% reduction in the 17-item Hamilton Rating Scale for Depression score) between agomelatine and placebo were 14.8% (95% CI 1.5–27.4),\(^89\) 15.2% (3.3–26.4),\(^87\) and 19.0% (6.5–31.5).\(^88\)

However, the wider set of studies of agomelatine now available highlights the more general problem encountered in the evaluation of new antidepressants—that separation from placebo is an inconsistent finding.\(^14\) As with other new drugs, agomelatine seems to be more effective in patients with more severe depression.\(^3\)–\(^5\) Whether agomelatine is more effective in patients with specific abnormalities in circadian function or more severe sleep disturbance is yet to be established.

In the active comparator trials, agomelatine (25–50 mg) had similar efficacy to venlafaxine (75–150 mg; extended-release 150 mg)\(^91\) and was more efficacious than fluoxetine (20–40 mg),\(^92\) and sertraline (50–100 mg).\(^91\) Significant improvements on a range of sleep variables, including improved sleep quality (mean difference 5.63, 95% CI 0.85–10.41, p=0.021), reduced wake after sleep onset (4.86, 0.23–9.49, p=0.040), and fewer insomnia reports (0.37, 0.01–0.72, p=0.044) were found with agomelatine than with venlafaxine.\(^91\)

In a long-term prevention of depression relapse trial,\(^96\),\(^99\) the final relapse rate with agomelatine at 24 weeks was 20.6% compared with 41.4% for placebo (a difference of 20.8% [95% CI 11.0–30.0]) and agomelatine at 10 months was 23.9% versus 50.0% for placebo (approximate difference of relapse estimates 26.4% [95% CI 12.7–39.0]). Data from two other relapse prevention trials did not indicate that agomelatine was more efficacious than placebo (table 4). Finally, by contrast with paroxetine, agomelatine does not seem to be associated with discontinuation symptoms.\(^97\)

### Table 5: Side-effects associated with agomelatine reported in placebo-controlled and active comparator trials

<table>
<thead>
<tr>
<th></th>
<th>Proportion reporting side-effects (agomelatine)*</th>
<th>Proportion reporting side-effects (comparator)*</th>
<th>Side-effects associated with agomelatine†</th>
<th>Side-effects significantly more prevalent with agomelatine than with comparator</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Placebo-controlled trials</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Agomelatine 25 mg per day(^90)</td>
<td>51.1% (70 of 137)</td>
<td>54.7% (76 of 139)</td>
<td>Headache (6.6%)</td>
<td>None</td>
</tr>
<tr>
<td>Agomelatine 25–50 mg per day(^90)</td>
<td>42.4% (50 of 128)</td>
<td>42.5% (51 of 120)</td>
<td>Headache (5.1%), fatigue (5.1%)</td>
<td>None</td>
</tr>
<tr>
<td>Agomelatine 25–50 mg per day(^90)</td>
<td>57.5% (65 of 106)</td>
<td>62.9% (66 of 105)</td>
<td>Dizziness (9.3%), nasopharyngitis (6.5%), influenza (6.5%)</td>
<td>None</td>
</tr>
<tr>
<td>Agomelatine 25–50 mg per day(^90)</td>
<td>70.3% (232 of 330)</td>
<td>65.5% (108 of 165)</td>
<td>Headache (13.3%), somnolence (9.3%), dizziness (7.3%), diarrhoea (7.3%), nausea (6.1%), fatigue (5.8%), sedation (5.2%), nasopharyngitis (5.2%)</td>
<td>None</td>
</tr>
<tr>
<td>Agomelatine 25–50 mg per day(^90)</td>
<td>75.1% (244 of 325)</td>
<td>74.6% (126 of 169)</td>
<td>Headache (16.3%), nausea (12.0%), diarrhoea (10.5%), dizziness (8.6%), dry mouth (7.1%), somnolence (7.1%), sedation (6.8%), fatigue (5.2%), insomnia (5.2%)</td>
<td>None</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Active comparator trials</strong></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Agomelatine 25–50 mg per day vs Sertraline 50–100 mg per day(^92)</td>
<td>48.0% (73 of 152)</td>
<td>49.1% (78 of 159)</td>
<td>Headache (8.6%), dry mouth (5.3%)</td>
<td>None</td>
</tr>
<tr>
<td>Agomelatine 25–50 mg per day vs Venlafaxine 75–150 mg per day(^94)</td>
<td>51.2% (85 of 166)</td>
<td>57.1% (96 of 168)</td>
<td>Headache (9.6%), nausea (6.0%)</td>
<td>None</td>
</tr>
<tr>
<td>Agomelatine 50 mg per day vs Venlafaxine (extended release) 150 mg per day(^94)</td>
<td>20.4% (28 of 137)</td>
<td>38.1% (53 of 139)</td>
<td>Nausea (11.7%), headache (10.2%), upper respiratory tract infections (7.3%)</td>
<td>None</td>
</tr>
<tr>
<td>Agomelatine 25–50 mg per day vs Fluoxetine 20–40 mg per day(^94)</td>
<td>57.2% (143 of 250)</td>
<td>56.3% (148 of 263)</td>
<td>Headache (16.0%), nausea (8.0%), somnolence (6.0%)</td>
<td>None</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Prevention of relapse</strong></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Agomelatine 25–50 mg per day vs Placebo (24 weeks)(^95)</td>
<td>51.5% (85 of 165)</td>
<td>52.3% (91 of 174)</td>
<td>Headache (7.9%), nasopharyngitis (6.7%), back pain (5.5%)</td>
<td>None</td>
</tr>
<tr>
<td>Agomelatine 25–50 mg per day vs Placebo (44 weeks)(^95)</td>
<td>59.4% (98 of 165)</td>
<td>56.9% (99 of 174)</td>
<td>Headache (9.7%), nasopharyngitis (9.1%), back pain (6.7%)</td>
<td>None</td>
</tr>
</tbody>
</table>

*All side-effects recorded via clinician-elicited patient self-report and physical examination. †Side-effects reported in more than 5% of patients on agomelatine. ‡Treatment-related side-effects. Kasper and Hamon\(^6\) provide further details about side-effects of agomelatine.

Published online May 18, 2011 DOI:10.1016/S0140-6736(11)60095-0
As agomelatine is not associated with increased levels of serotonin, it does not produce the same side-effect profile that is commonly seen with other novel antidepressants (notably, gastrointestinal changes, headaches, sexual difficulties, psychomotor agitation, or weight gain) and does not have the risk of other major adverse events (such as serotonin syndrome or serotonin discontinuation symptoms). 101–104 Although nausea, dizziness, and headache are the symptoms most commonly reported by patients treated with agomelatine, these side-effects were reported at similar rates by those receiving placebo (table 5). 105

The side-effect profile of agomelatine is equivalent to that of placebo for many common effects associated with antidepressant drugs, including weight gain, sexual functioning, and discontinuation effects (table 5). 105

Conclusions
Melatonin analogues provide a new and efficacious mechanism for producing notable phase shifts in human beings. Although these drugs have been mainly studied for sleep disorders, they also have the potential to be used as primary or adjunctive drugs across a wider range of neuropsychiatric disorders characterised by persistent circadian disturbance. Importantly, only agomelatine (which also binds 5-HT2C receptors) has been reported to have clinically significant antidepressant effects. Because of its favourable adverse effect and safety profile, and the potential to help to restore circadian function between depressive episodes, this drug might occupy a unique place in the management of some patients with severe depression and other major mood disorders.

References


